Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...
BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious ...
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development ...
Fulcrum granted the new employees 30,400 options to purchase shares of the company’s common stock at an exercise price of $10 ...
BOULDER, Colo., Aug. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics ...
Each stock option granted on January 5, 2026 has an exercise price per share equal to $47.07, Vera Therapeutics’ closing ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal ...
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback